0.6185
Ovid Therapeutics Inc Borsa (OVID) Ultime notizie
Ovid Therapeutics Inc. Stock Analysis and ForecastFree Market Dynamics Reports - PrintWeekIndia
Ovid Therapeutics Sells Ganaxolone Royalty Rights for $7M to Immedica Pharma - MSN
What drives Ovid Therapeutics Inc. stock priceConsistently profitable trades - PrintWeekIndia
Why Ovid Therapeutics Inc. stock attracts strong analyst attentionFree Real-Time Market Predictions - Newser
Is Ovid Therapeutics Inc. a good long term investmentLightning-fast capital gains - Autocar Professional
Ovid Therapeutics shares rise 4.29% premarket after announcing participation in the BTIG Virtual Biotechnology Conference. - AInvest
Ovid Therapeutics to Participate in the BTIG Virtual Biotech Conference - GlobeNewswire
12 Best Penny Stocks Under $1 to Buy Now - Insider Monkey
What analysts say about Ovid Therapeutics Inc. stockBreakout profit opportunities - Autocar Professional
Ovid Therapeutics' Strategic Position in the Seizure and CNS Disorder Market: Pipeline Innovation and Partnership Potential - AInvest
Ovid Therapeutics to Participate in the BTIG Virtual Biotech Conference | OVID Stock News - GuruFocus
Brain Medicine Developer Ovid Therapeutics Reveals Latest Progress at Major BTIG Biotech Conference - Stock Titan
July 2025's Top Penny Stocks To Watch - simplywall.st
Ovid Therapeutics Stock Soars 13.88% on Investor Optimism - AInvest
Ovid Therapeutics (NASDAQ:OVID) Receives Average Rating of “Buy” from Analysts - Defense World
Ovid Therapeutics (NASDAQ:OVID) Stock Rating Upgraded by Wall Street Zen - Defense World
What makes Ovid Therapeutics Inc. stock price move sharplyFree Access to Community with 300% Return - beatles.ru
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Ovid Therapeutics Surges 25% Amid Analyst Hype and Strategic Pipeline Progress - AInvest
Oliveda International, Inc. (OLVI) Announces Over 70% Growth in the First Half of 2025 - Yahoo.co
How Ovid Therapeutics Inc. stock performs during market volatilityTop Rated Trade Entries - Newser
Ovid Therapeutics (NASDAQ:OVID) Stock Price Down 2% – Time to Sell? - Defense World
Ovid Therapeutics Approves Key Proposals at Annual Meeting - The Globe and Mail
Local Bounti (LOCL) insider files Form 144 to sell 3,500 shares - Stock Titan
Ovid Therapeutics Sells Ganaxolone Royalties to Immedica - TipRanks
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):